TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine for Benign Headache in the ED

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-65 years old~2. Diagnosis of benign or primary headache~Exclusion Criteria:~1. Hypersensitivity or allergy to bupivacaine (amide anesthetics) or prochlorperazine or other drugs in the same class, dopaminergic blockers.~2. Overlying signs of infection at site of injection (Erythema, purulence, open skin)~3. Neck pathology ( History of surgery to the cervical spine, History of surgical hardware in place, Documented disc abnormality, History of vertebral artery or carotid artery dissection, Torticollis)~4. Intracranial abnormality/pathology (Tumor, Hemorrhage, Concussion or post concussive syndrome)~5. History of increased intracranial pressure (ICP)~6. A known history of extrapyramidal symptoms, dystonia, parkinsonism, tardive dyskinesia or neuroleptic malignant syndrome~7. Known pregnancy~8. Narcotic seeking patients as determined by the treating physician with optional assistance from medical record review and North Carolina Drug Database

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- standard care (Type: ACTIVE_COMPARATOR): intravenous Prochlorperazine
- treatment (Type: EXPERIMENTAL): 0.5% bupivacaine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical and Actigraphic Profile of Young Patients Admitted for Attempted Suicide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* children/adolescents admitted after a suicide attempt~Exclusion Criteria:~* severe depression~* mental retardation~* pervasive developmental disorder~* active psychotic episode,~* drug and alcohol abuse at the time of admission~* organic sleep-wake disorders (sleep-related respiratory and motor disorders, narcolepsy)~* any contraindication formulated by the clinical team~* patients not covered by French national health insurance, patients deprived of their freedom as stipulated in Article L.1121-6 of the French Public Health Code

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- suicide attempt (Type: EXPERIMENTAL): questionnaires actigraphic recording

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Assessment of Polyp Histology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing screening colonoscopy~Exclusion Criteria:~* Missing consent~* No screening colonoscopy (diagnostic colonoscopy because of symptoms)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hi Line (Type: ACTIVE_COMPARATOR): This arm is examined with latest generation HDTV colonoscopes
- Classic Line (Type: NO_INTERVENTION): control group undergoing colonoscopy with older generation scope currently in use in most centers

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of a Slotted Anoscope That Facilitates Hemorrhoidectomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Are at least 18 years of age~* Are willing to give consent and comply with evaluation and treatment schedule~* Meet institutional criteria for excisional hemorrhoidectomy~* Are able to understand and complete study questionnaires.~Exclusion Criteria:~* Previous Hemorrhoid surgery~* Chronic daily narcotic use~* Chronic Nonsteroidal Anti-inflammatory Drug use two weeks prior to procedure~* Internal hemorrhoids that may be suitable for office management (surgeon discretion)~* Fecal or urinary incontinence~* Inflammatory Bowel Disease (Crohns, ulcerative colitis)~* Acutely thrombosed hemorrhoids (surgeon discretion)~* Evidence of acute sepsis or the presence of a fistula~* Anal stricture.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Active postdural puncture headache within 7 days after neuraxial analgesia/anesthesia~* Age ≥ 18 years.~* ASA physical status ≤ 3~Exclusion Criteria~* Known coagulopathy~* Known nasal septal deviation or abnormalities~* Medical conditions contraindicated to bupivacaine or the nasal applicator (according to the product labeling)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Acitve (Type: ACTIVE_COMPARATOR): This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I-II~* Age: 18-64 years~* Female~* Surgery: Gynecologic hysteroscopy~* Language: English speaking~* Consent: Obtained~Exclusion Criteria:~* Pregnant or breast feeding~* Significant arrhythmia or high degree atrioventricular nodal block~* Significant hepatic or renal dysfunction~* Chronic use or addiction to opiates or sedatives~* History of heavy alcohol usage (\>4 drinks/day)~* Psychiatric or emotional disorder~* Chronic use of α2-agonists~* Patients with OSA or BMI greater than 30~* Allergy to study drug or anesthetic medications utilized in the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Continuous infusion of placebo during operative procedure
- Active Comparator (Type: ACTIVE_COMPARATOR): Administration of Dexmedetomidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with classic SCID phenotype (\<400 CD3/ul or maternally engrafted and \<10% of normal PHA lymphoproliferative response). Genotypic identification is preferable, but not required.~* Patients must have an acceptable stem cell donor (HLA matched relative, 9 or 10/10 HLA-matched unrelated, or haplocompatible relative).~Exclusion Criteria:~* Patients with leaky SCID syndromes, Omenn's Syndrome, reticular dysgenesis, ADA deficiency~* Lansky score \<60%~* Patient with expected survival \<4 weeks (including disseminated CMV infection involving lungs and/or CNS)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 3 Years
- Healthy Volunteers: f

Study Arms:
- T-cell Graft Permissive SCID (Type: EXPERIMENTAL): Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only
- T-cell Graft Resistant SCID (Type: EXPERIMENTAL): Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Distant metastatic disease confirmed by histology, cytology, or strong clinical evidence~* Measurable disease~* No known brain or CNS metastases~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 70 and over OR~* Under 60~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Hemoglobin at least 9 g/dL~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than upper limit of normal (ULN)~* SGOT or SGPT no greater than 1.5 times ULN (2.0 times ULN if liver metastases are present)~* Alkaline phosphatase no greater than 1.5 times ULN (2.0 times ULN if liver metastases are present)~Renal:~* Creatinine no greater than ULN~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* HIV negative~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent immunotherapy for breast cancer~Chemotherapy:~* Prior adjuvant or neoadjuvant chemotherapy allowed~* Prior adjuvant taxanes allowed~* No other concurrent chemotherapy for breast cancer~Endocrine therapy:~* Prior hormonal therapy in the adjuvant setting or for metastatic disease allowed~* No concurrent hormonal therapy for breast cancer~Radiotherapy:~* No concurrent radiotherapy for breast cancer~Surgery:~* Not specified~Other~* No more than 1 prior regimen for advanced, recurrent, or metastatic disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- docetaxel (Type: EXPERIMENTAL): docetaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to provide informed consent~* Age: 18-96 years~* Affected foot/shoe size \<46 (approximate foot length\< 29,5 cm)~* Receiving hemodialysis ≥3 times per week for 1 hour per treatment OR~* Peripheral arterial disease and leg ulcer~Exclusion criteria:~* Incapable to consent voluntarily, i.e. patients who are not able to consent due to their mental status, or who are not willing or able to perform the negative pressure therapy in a sitting position~* Not adhering to the INP therapy program~* Patients with an expected life-span less than 3 months~* Patients in whom the remaining limb is non-functional, for example due to previous stroke~* Patients in which a deep venous thrombosis or pulmonary embolism is suspected~* Limbs with uncontrolled infection~* Previous lumbar sympathectomy~* Bilateral amputation of lower extremity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 96 Years
- Healthy Volunteers: f

Study Arms:
- single-case design (Type: EXPERIMENTAL): The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of extensive-stage small cell lung cancer~* No untreated brain metastases~  * No active symptoms related to brain metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Hemoglobin ≥ 9.0 g/dL~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)~* Creatinine ≤ 1.5 times ULN~* INR \< 1.5 or PT/PTT normal~* No history of cardiac disease, including any of the following:~  * NYHA class III-IV congestive heart failure~ * Unstable angina (i.e., anginal symptoms at rest)~ * Onset of angina within the past 3 months~ * Myocardial infarction within the past 6 months~* No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy~* No uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 90 mm Hg, despite optimal medical management~* No thrombolic or embolic events, such as cerebrovascular accident or transient ischemic attacks, within the past 6 months~* No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within the past 4 weeks~* No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks~* No known HIV infection or chronic hepatitis B or C infection~* No active clinically serious infection \> CTCAE grade 2~* No serious non-healing wound, ulcer, or bone fracture~* No evidence or history of bleeding diathesis or coagulopathy~* No significant traumatic injury within the past 4 weeks~* No known or suspected allergy to sorafenib tosylate or to any other drug given during the study~* No condition that would impair the patient's ability to swallow whole pills~* No known malabsorption problem~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception~  * Male patients must use effective contraception during and for ≥ 3 months after completion of sorafenib tosylate~PRIOR CONCURRENT THERAPY:~* Prior radiotherapy to the brain allowed~* No prior chemotherapy~* More than 4 weeks since prior major surgery or open biopsy~* No concurrent Hypericum perforatum (St. John's wort) or rifampin~* Concurrent anti-coagulation treatment, such as warfarin or heparin, allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sorafenib, Cisplatin, and Etoposide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Natural Orifice Translumenal Endoscopic Surgery (NOTES) Cystgastrostomy for the Treatment of Pancreatic Pseudocysts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (over 18 years old) patients who are able to provide informed consent for this surgical procedure~2. Patients scheduled to undergo non-emergent surgical treatment removal of pancreatic pseudocyst~Exclusion Criteria:~1. Inability to provide informed consent~2. Patients who, in the opinion of the investigator, would not be appropriate for enrollment into this experimental research project~3. Patients who are deemed to be unstable from a medical standpoint to undergo pancreatic surgery~4. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- NOTES pancreatic pseudocystgastrostomy (Type: EXPERIMENTAL): Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-Assisted Lumbar Puncture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who registered for an emergency or inpatient encounter between 5/22/2017 and 5/08/2018~2. Males or females 18 years of age or older~3. Patients who have been identified as requiring a lumbar puncture for any therapeutic or diagnostic or therapeutic indication, as decided by the neurology staff physicians, residents, or advanced practice providers.~Exclusion Criteria:~1. Patients who are not capable of providing consent for participation in research and do not have an authorized relative or power of attorney to consent in their stead.~2. Patients who require lumbar puncture in an emergency, time dependent fashion and in whom a possible delay could conceivable have a negative clinical impact.~3. Patients with known abnormal lumbar spinal anatomy or prior extensive surgical fusion such that fluoroscopic or CT guidance is determined to be more clinically appropriate by the treating physicians.~4. BMI greater than 60~5. Absolute contraindication to lumbar puncture such as uncorrected coagulopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: OTHER): Traditional landmark-based lumbar puncture technique by palpation
- Experimental (ultrasound) (Type: EXPERIMENTAL): Use of point-of-care ultrasound to identify bony landmarks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All subjects age 18 and older who have given written informed consent~2. Undergoing cardiac surgery cardiopulmonary bypass (CBP) at Weill Cornell Medical Center~Exclusion Criteria:~1. Subjects on anticoagulation medications including:~   * Clopidogrel, ticagrelor, prasugrel with platelet function analyzer-100 assay closure time (CT) prolonged greater than 15%~  * Last doses of dabigatran, rivaroxaban, apixaban within 72 hours~  * Warfarin with international normalized ratio (INR) greater than 1.5~2. Positive pregnancy test, pregnancy or lactation~3. Thrombocytopenia: platelet count less than 100,000 u/L~4. Emergency procedures~5. Proof or suspicion of a congenital or acquired coagulation disorder (e.g. von Willebrand Factor or via severe liver disease)~6. Participation in another randomized clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- RiaSTAP Arm (Type: ACTIVE_COMPARATOR): Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
- Cryopreciptiate Arm (Type: ACTIVE_COMPARATOR): Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility